TAK - CIK 0001395064
TAKEDA PHARMACEUTICAL CO LTD trades as TAK and has a market capitalization of $24.43 B, making it the #542 largest US-listed company by market value. This page tracks TAKEDA PHARMACEUTICAL CO LTD through 609 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| SD | - | 2026-05-22 |
| 6-K | - | 2026-05-19 |
| 6-K | - | 2026-05-13 |
| 6-K | - | 2026-05-13 |
| New insider ownership | 3 | 2026-05-05 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
| Insider trade | 4 | 2026-04-28 |
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
2026 Innovators in Science Award: Takeda and Nature Name Grand Prize Winner
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results.
The largest companies sharing TAKEDA PHARMACEUTICAL CO LTD's SEC industry classification (pharmaceutical preparations).
TAKEDA PHARMACEUTICAL CO LTD (TAK) has a market capitalization of $24.43 B as of 2026-06-10, ranking #542 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.